| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
32,994 |
27,570 |
$2.05M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,277 |
4,810 |
$480K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
2,525 |
2,257 |
$219K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
14,339 |
12,989 |
$182K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
2,496 |
2,390 |
$161K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,445 |
2,338 |
$160K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,157 |
2,048 |
$140K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,651 |
1,564 |
$107K |
| 87449 |
|
3,047 |
2,847 |
$69K |
| 90686 |
|
2,541 |
2,514 |
$49K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,370 |
1,317 |
$36K |
| D1206 |
Topical application of fluoride varnish |
2,145 |
2,045 |
$35K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
388 |
351 |
$33K |
| 90670 |
|
1,782 |
1,715 |
$33K |
| 90648 |
|
1,398 |
1,340 |
$26K |
| 90633 |
|
1,296 |
1,252 |
$24K |
| 99173 |
|
4,887 |
4,598 |
$20K |
| 36416 |
|
8,284 |
7,859 |
$20K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
450 |
422 |
$19K |
| 90680 |
|
996 |
959 |
$19K |
| 83655 |
|
1,120 |
1,070 |
$16K |
| 81002 |
|
5,306 |
4,954 |
$15K |
| 90723 |
|
797 |
749 |
$15K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,464 |
1,281 |
$14K |
| 90651 |
|
677 |
656 |
$13K |
| 87807 |
|
1,109 |
1,026 |
$11K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
364 |
345 |
$11K |
| 87430 |
|
812 |
723 |
$8K |
| 96127 |
|
2,089 |
1,963 |
$6K |
| 87634 |
|
308 |
292 |
$6K |
| 90734 |
|
250 |
241 |
$5K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
468 |
458 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
270 |
232 |
$4K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
102 |
100 |
$4K |
| 90661 |
|
156 |
148 |
$4K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
236 |
231 |
$4K |
| 90674 |
|
193 |
187 |
$4K |
| 90672 |
|
153 |
152 |
$3K |
| 85018 |
|
7,245 |
6,900 |
$2K |
| 90619 |
|
129 |
113 |
$2K |
| 90715 |
|
97 |
96 |
$2K |
| 86308 |
|
346 |
320 |
$2K |
| 90696 |
|
96 |
96 |
$2K |
| 90620 |
|
96 |
90 |
$2K |
| 90710 |
|
91 |
91 |
$2K |
| 90716 |
|
95 |
90 |
$2K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
43 |
42 |
$1K |
| 99460 |
|
14 |
13 |
$1K |
| 90707 |
|
60 |
56 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
520 |
449 |
$731.81 |
| 90698 |
|
26 |
25 |
$494.75 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
512 |
465 |
$461.18 |
| 94664 |
|
31 |
26 |
$260.00 |
| 90685 |
|
13 |
13 |
$257.27 |
| 96161 |
|
87 |
86 |
$252.84 |
| 82947 |
|
51 |
46 |
$184.00 |
| 36415 |
Collection of venous blood by venipuncture |
72 |
68 |
$140.00 |